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Many venom peptides are potent and selective inhibitors of voltage-gated ion channels, including 
channels that are validated therapeutic targets for treatment of a wide range of human diseases. 
However, the development of novel venom-peptide-based therapeutics requires an understanding 
of their mechanism of action. In the case of voltage-gated ion channels, venom peptides act either 
as pore blockers that bind to the extracellular side of the channel pore or gating modifiers that bind 
to one or more of the membrane-embedded voltage sensor domains. In the case of gating 
modifiers it has been debated whether the peptide must partition in to the membrane to reach its 
binding site. In this study we used surface plasmon resonance, fluorescence spectroscopy and 
molecular dynamics to directly compare the lipid binding properties of two gating modifiers (µ-
TRTX-Hd1a and ProTx-I) and two pore-blockers (ShK and KIIIA). Only ProTx-I was found to bind 
to model membranes. Our results provide further evidence that the ability to insert into the lipid 
bilayer is not a requirement to be a gating modifier. In addition, we characterised the surface of 
ProTx-I that mediates its interaction with neutral and anionic phospholipid membranes and show 





• The first direct comparison of lipid-binding properties of two pore blockers and two gating 
modifiers.  
• Venom-derived pore blockers do not interact with lipid membranes. 
• The venom-derived gating modifier peptide ProTx-I interacts strongly with phospholipid 
membranes, with a preference for anionic lipid-containing membranes. 
• The venom-derived gating modifier Hd1a does not bind to phospholipid membranes. 
• Interaction with lipid membranes is not a prerequisite for potent gating-modifier activity. 
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LUV  Large unilamellar vesicle  
NaV  Voltage-gated sodium channel  
PBs  Pore blocker, pore blocking peptide 
POPC  1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine  
POPS  1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine 
ProTx-I Protoxin1, β-theraphotoxin-Tp1a 
VGICs  Voltage-gated ion channels 
VSDs  Voltage-sensing domains 
SASA  Solvent accessible surface area 










Voltage-gated ion channels (VGICs) play crucial roles in diverse physiological processes [1, 2], 
and are drug targets for a range of diseases, including chronic pain, multiple sclerosis, epilepsy 
and cardiac arrhythmia [3-5]. Venoms from arachnids, sea anemones, cone snails, and other 
venomous animals are a rich source of pharmacologically active peptides [6-9] that target VGICs, 
especially voltage-gated sodium (NaV), potassium (KV) and calcium (CaV) channels [1, 10-16]. 
These peptides are often highly potent and selective and have thus attracted much interest as 
potential lead molecules for pharmaceutical development [17-20]. However, full exploitation of their 
therapeutic potential requires an understanding of their mechanism of action.  
 
VGICs are transmembrane proteins responsible for the selective transport of ions across cell 
membranes in response to changes in the membrane potential. They share a common architecture 
consisting of a central pore domain, responsible for ion conduction, and four voltage-sensing 
domains (VSDs) that turn the channel on or off in response to changes in the transmembrane 
potential [1, 21-25]. The gating cycle of VGICs comprises three distinct states: closed (resting), 
open (activated) and in some cases also an inactivated state. Venom peptides interfere with the 
gating cycle via two distinct mechanisms. Some peptides inhibit the channel by binding to the pore 
domain and preventing ion conduction. These peptides are referred to as pore blockers (PBs). 
Alternatively, some venom peptides can bind to a VSD and alter the kinetics and gating behaviour 
by changing the relative stability of the closed, open or inactivate states of the channel [16, 21]. 
Peptides acting via this mechanism are called gating modifiers (GMs). As the pore domain is 
solvent accessible it is likely that the binding affinity of PBs is primarily governed by peptide-protein 
interactions and is independent of the lipid environment surrounding the VGIC protein. However, 
this has not been studied systematically. In contrast, the VSDs are largely buried in the membrane, 
which potentially prevents gating modifier peptides directly accessing their binding site on the VSD. 
Thus, gating modification is potentially a three-component system involving the peptide, the VSD 
and the surrounding lipid membrane. The role of membrane partitioning and specific peptide-lipid 
interactions in the mechanism of GMs remains an open question. Some studies have shown that 
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the tarantula toxins VsTx1 [26, 27], SGTx1 [28, 29], hanatoxin [29, 30] and ProTx-II [31, 32], as 
well as other GMs [31], partition into phospholipid bilayers. This has led to the suggestion that GMs 
act via a ‘membrane-access mechanism’ [27]. However, other studies have shown that gating 
modifier peptides such as huwentoxin-IV [32] do not partition into membranes [31-34] or their 
binding to the VSD is independent of the ability of the peptide to insert into the lipid bilayer [33]. 
Furthermore, contradictory results have been reported regarding the requirement of anionic 
phospholipids for the ability of some gating modifier peptides to insert into lipid membranes. Lee 
and McKinnon reported that VsTx1 binds to membranes containing some anionic phospholipids 
and also to membranes comprised solely of zwitterionic phospholipids [27]. In contrast, Jung et al. 
claimed that anionic lipids are essential for membrane partitioning of VsTx1 [26]. Similarly, Milescu 
et al. [29] reported that SGTx1 binds to neutral and anionic phospholipids whereas in a later study 
Posokhov et al. reported that membrane partitioning of SGTx1 only occurs in the presence of 
anionic lipids [34].  
 
A number of studies have investigated the nature of the interaction between lipids and GMs, 
including the position of the peptide in the lipid bilayer [26, 28-30, 35-37]. Based on these studies it 
has been suggested that many gating modifier peptides are localised at the water-lipid interface 
and that the orientation of the peptide in the membrane and/or specific lipid-peptide interactions 
might be important for GMs to bind to VSDs. The position of the peptides and their orientation at 
the water-lipid interface might result from their amphipathic character. Although there is increasing 
evidence that the originally proposed ‘membrane-access mechanism’ [27] cannot be generalised 
to all GMs, to date there has not been a direct comparison of the phospholipid binding activities of 
PBs and GMs. 
 
In the current study the ability of two PBs and two GMs (Fig. 1) to bind phospholipid bilayers was 
investigated using surface plasmon resonance (SPR), fluorescence spectroscopy and molecular 
dynamics (MD) simulations. The two PBs we investigated are: (i) ShK, a 35-residue peptide 
isolated from the sea anemone Stichodactyla helianthus [14, 38-41]. ShK potently blocks Kv1.3 
and is currently in Phase IIa clinical trials for the treatment of autoimmune diseases; (ii) KIIIA, a 16-
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residue µ-conotoxin isolated from the cone snail Conus kinoshitai which inhibits tetrodotoxin-
sensitive NaV channels [42-45]. These two peptides were compared to two GMs: (i) µ-TRTX-Hd1a 
(Hd1a), a 36-residue peptide isolated from the tarantula Haplopelma doriae that selectively inhibits 
NaV1.1 and NaV1.7 [19] and (ii) ProTx-I, a promiscuous 35-residue peptide isolated from the 
tarantula Thrixopelma pruriens that inhibits NaV, KV and CaV channels [15, 46, 47]. The interactions 
of these peptides with phospholipids have not been investigated previously.  
 
Our study shows that PBs exhibit only a weak affinity for lipid membranes. Of the two GMs tested, 
Hd1a interacted poorly with phospholipid bilayers, whereas ProTx-I showed concentration-
dependent binding to both neutral and anionic membranes. Fluorescence spectroscopy 
measurements and MD simulations of ProTx-I in the presence of phospholipid membranes 
revealed that the peptide preferentially binds to the water-lipid interface and that residues on or 
near the hydrophobic face of the peptide probably form the dominant lipid interaction surface of 
ProTx-I. 
 
2. Materials and methods  
 
2.1. Peptide synthesis  
ShK, ProTx-I and KIIIA were chemically synthesised using standard Fmoc solid-phase synthesis 
protocols using a Symphony peptide synthesiser (Protein Technologies Inc). ShK and ProTx-I 
were assembled on 2-chlorotrityl resin at 0.25 mmol scale and KIIIA was assembled on rink-amide 
resin at 0.25 mmol scale to produce an amidated C-terminal. The amino acid protecting groups 
used were Cys(Trt), Asp(tBu), Glu(tBu), Lys(Boc), Asn(Trt), Arg(Pbf), Ser(tBu), Thr(tBu), Trp(Boc), 
His(Trt), Gln(Trt) and Tyr(tBu). The peptides were released from the resin and amino acid side 
chain simultaneously cleaved by incubation with triisopropylsilane (TIPS):H2O:TFA (2:2:96, v/v/v) 
for 2.5 h at room temperature. Trifluoroacetic acid (TFA) was evaporated under vacuum, and 
peptides precipitated with ice-cold diethyl ether. Peptides were dissolved in 50% acetonitrile 
(0.05% TFA) and lyophilized. The crude linear peptides were purified using reversed phase high-
performance liquid chromatography (RP-HPLC) (0–80% B over 80 min, flow rate 8 mL/min, solvent 
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A; 0.05% TFA, solvent B 90% acetonitrile (ACN)/0.045% TFA on a Shimadzu RP-HPLC) and their 
molecular mass determined using electrospray mass spectrometry (ESI-MS). Purified peptides 
were oxidised as described previously for KIIIA [48], ShK [39] and ProTx-I [47]. Recombinant Hd1a 
was produced as described previously [19]. Peptide purity was >95%, as determined using 
analytical-HPLC, and the correct disulfide-bond connectivity was established using 1D and 2D 
NMR spectroscopy. The overall hydrophobicity of the peptides was assessed by comparing the 
retention times obtained by analytical RP-HPLC using a 2%/min gradient of solvent B (90% 
ACN/0.1% formic acid) against solvent A (0.1% formic acid). 
 
2.2. Preparation of lipid vesicles 
Synthetic phospholipids, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-
palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (POPS), were purchased from Avanti polar lipids. 
Lipid films were prepared by solubilising POPC, or a mixture of POPC and POPS (4:1 molar ratio), 
in chloroform (spectroscopic grade, Sigma); the solvent was evaporated under nitrogen flow and 
left under vacuum for ~16 h. Small unilamellar vesicles (SUVs, 50 nm diameter) or large 
unilamellar vesicles (LUVs, 100 nm) composed of POPC or POPC/POPS (4:1) were obtained by 
hydration of the lipid films with HEPES buffer (10 mM HEPES, 150 mM NaCl, pH 7.4) followed by 
freeze-thaw fracturing and sizing by extrusion, as described previously [49]. SUVs were used in 
surface plasmon resonance whereas LUVs were used in fluorescence spectroscopy studies [50]. 
 
2.3. Peptide-lipid interactions followed by Surface Plasmon Resonance  
Peptide samples were prepared in HEPES buffer and the concentration quantified by absorbance 
at 280 nm based on extinction coefficients calculated from the contribution of aromatic residues 
and disulfide bonds as follows: 7365 M-1.cm-1 for Hd1a; 18365 M-1.cm-1 for ProTx-I; 18365 M-1.cm-1 
for ShK and 5875 M-1.cm-1 for KIIIA. 
 
SPR measurements were conducted at 25 ºC using a Bioacore 3000 instrument (GE Healthcare) 
with a L1 biosensor chip. All solutions were freshly prepared and filtered (0.22 µm pore); HEPES 
buffer was used as running buffer. Peptide samples were injected over lipid bilayers deposited 
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onto the chip surface as described previously [49, 51]. Varying peptide concentrations were tested 
(1–64 µM) based on the ability of each peptide to bind to a POPC or POPC/POPS (4:1) bilayer. 
Response units (RU) were converted into mass of peptide or lipid assuming 1 RU=1 pg/mm2 [52]. 
The amount of peptide bound to the lipid bilayer was calculated at a reporting point at the end of 
the association phase (t = 170 s) and normalised to the amount of lipid deposited onto the chip 
surface and represented as a peptide-to-lipid ratio (P/L; mol/mol) [53]. The ability of a peptide to 
bind to a membrane of a given lipid composition can be inferred based on the P/L signal obtained 
at the end of the association curve, and/or on the dissociation rate. Sensorgrams obtained with 
peptides having low affinity for a certain lipid membrane typically give a SPR binding response of ≤ 
0.05 P/L (mol/mol) when injected at concentrations ≥ 30 µM and/or have a very fast dissociation 
rate reaching P/L close to 0 after 5–10 s of dissociation [51, 54].   
 
2.3 Peptide-lipid interactions followed by fluorescence spectroscopy 
Changes in the membrane dipolar potential upon insertion of peptides into the lipid bilayer were 
examined using the dye 4-[2-[6-(dioctylamino)-2-naphthalenyl]ethenyl]-1-(3-sulfopropyl) (di-8-
ANEPPS; Invitrogen) [50]. Fluorescence excitation spectra (λemission = 558 nm) of LUVs composed 
of 200 µM POPC/POPS (4:1) and 4 µM di-8-ANEPPS were recorded in the absence and presence 
of 20 µM of each of the four toxins. Differential excitation spectra were calculated as described 
[50].  
 
ProTx-I is intrinsically fluorescent as it contains three Trp residues. Insertion of these Trp residues 
into lipid membranes was examined by steady-state fluorescence as described previously [50, 55]. 
Briefly, 25 µM of ProTx-I was titrated with LUVs composed of POPC/POPS (4:1) up to 4 mM of 
lipid concentration and fluorescence emission spectra recorded with excitation at 280 nm. Spectra 
were corrected for the blank, dilution and light dispersion due to addition of LUVs. 
 
Fluorescence emission quenching induced by acrylamide was used to examine whether the Trp 
residues are solvent exposed. Fluorescence emission intensity ((λexcitation at 290 nm and λemission at 
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348 nm) of 25 µM ProTx-I in the absence or presence of 1 mM POPC/POPS (4:1) was followed 
upon titration with acrylamide up to 100 mM. Data were fitted with the Stern-Volmer equation: 
𝐼!
𝐼
= 1 + 𝐾!" 𝑄  
in which I and I0 are the fluorescence intensity in the presence and absence of quencher, [Q] is the 
concentration of quencher and KSV is the Stern-Volmer constant. The quenching efficiency was 
compared with the calculated KSV as reported [50, 55]. All fluorescence measurements were 
conducted using a LS50 PerkinElmer fluorescence spectrophotometer using quartz cuvettes with 
0.5 cm length path. The peptide concentration range used in fluorescence methodologies is higher 
than the biological active concentrations due to the detection limits of fluorescence spectroscopy  
but this should not affect the interpretation of the results under the conditions of the current study. 
 
2.3. Molecular Dynamics simulations  
 
2.3.1.Simulations of ProTx-I in water  
Simulations of free peptide in water were performed to ensure the structure was equilibrated 
before simulating the peptide in the presence of a given lipid bilayer. The ProTx-I NMR structure 
2M9L.pdb [56] was used as a starting structure. The peptide was modelled with a NH3+ N-terminus 
and a COO– C-terminus. Disulfide bonds were modelled according to the NMR structure. Lys and 
His residues were simulated in their protonated state whereas Asp and Glu were modelled in their 
de-protonated state. The peptide was placed in a rectangular box and hydrated with water. The net 
charge was neutralised with Na+ and Cl– ions and further ions were added to give a final salt 
concentration of 100 mM NaCl. The system was energy minimised using a steepest descent 
algorithm and the solvent was equilibrated by simulating for 2-ns with position restraints on all 
backbone atoms of the peptide. The unrestrained peptide was simulated for 100 ns in duplicate, in 
with starting velocities were randomly assigned from Maxwellian distributions. The final 
conformations of the peptide from these simulations were used as starting structures for the 
simulations of ProTx-I in the presence of POPC and POPC/POPS (4:1) bilayers.  
 
2.3.2. Simulations of ProTx-I in the presence of a POPC membrane 
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Four simulation systems were built using the equilibrated peptides and a fully equilibrated lipid 
bilayer consisting of 128 POPC molecules [57] obtained from the Automatic topology builder (ATB) 
[58-60]. The peptide was positioned approximately 0.2–0.3 nm from the lipid bilayer in a random 
orientation. Each system was hydrated with water molecules and the net charge was neutralised 
with Na+ and Cl– ions and further ions were added to give a final salt concentration of 100 mM 
NaCl. The systems were energy minimised using a steepest descent algorithm and the solvent 
was equilibrated by simulating for 2-ns with position restraints on all backbone atoms of the 
peptide and all heavy atoms in the lipid molecules. Each of the four systems were then simulated 
for 300 ns in duplicate using randomly assigned starting velocities giving a total of eight 
independent simulations of 300 ns.   
 
2.3.3. Simulations of ProTx-I in the presence of POPC/POPS (4:1) 
A POPC/POPS (4:1) bilayer was prepared using the fully equilibrated lipid bilayer consisting of 128 
POPC molecules [57] obtained from ATB [58-60]. In each of the two leaflets, 13 randomly selected 
POPC molecules were replaced with POPS molecules to give a bilayer consisting of 102 POPC 
and 26 POPS molecules. This POPC/POPS bilayer was solvated with water molecules and the net 
charge was neutralised with Na+ and Cl– ions to give a final salt concentration of 100 mM NaCl. 
The system was energy minimised using a steepest descent algorithm and equilibrated for 100 ns. 
This equilibrated bilayer was used to set up four simulation systems of ProTx-I in the presence of 
POPC/POPS analogous to the simulations of ProTx-I in the presence of POPC. Each of the four 
systems was simulated for 300 ns giving a total of eight independent simulations of 300 ns.  
 
2.3.4. Simulation parameters  
All simulations were performed using GROMACS version 3.3.3 [61], in conjunction with the 
GROMOS 54A7 force field [62]. Parameters for POPC were taken from the revised GROMOS 
53A6 force field for lipids [63, 64]. The topology and parameters for POPS lipids were obtained 
from ATB [58-60]. Water was described using the simple point charge (SPC) water model [65]. All 
simulation systems were subjected to periodic boundary conditions using a rectangular box. Non-
bonded interactions were evaluated using a twin-range cut-off scheme. Interactions in the short 
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range were cut-off at 0.8 nm and were calculated every step, whereas interactions in the long-
range were cut-off at 1.4 nm and updated every two steps. To minimize the effect of truncating the 
electrostatic interactions beyond the 1.4 nm long-range cut-off, a reaction field correction was 
applied using a relative dielectric constant (εr) of 78.5 [66]. The reason why a reaction field was 
chosen to calculate the long range electrostatic was threefold. First, a reaction field is significantly 
computationally more efficient than lattice sum methods. Second, the force field used was 
parameterized for use with a 1.4 nm cutoff and reaction field, and third given the cutoff used there 
is very little difference between a reaction field and a lattice sum method such as PME including for 
lipid simulations. The SHAKE algorithm [67] was used to constrain covalent bond lengths during 
the simulation. The simulation temperature was maintained at a temperature of 298 K using a 
Berendsen thermostat [68] with a coupling constant (τP) of 0.1 ps. For simulations of ProTx-I in 
water, the pressure was maintained at 1 bar by isotropically coupling the system to an external 
bath using the method of Berendsen [68] with an isothermal compressibility of 4.5 × 10−5 bar−1 and 
τP of 1 ps. The Berendsen methods were used as they lead to a continuous trajectory and do not 
require the introduction of stochastic forces or lead to oscillations. For simulations of ProTx-I in the 
presence of a POPC and POPC/POPS, an anisotropic pressure coupling using the same 
parameters as for simulations of ProTx-I in water was used. In all simulations, a 2 fs time step was 
used and configurations were saved every 100 ps for analysis. All images were produced using 
VMD [69].  
 
2.3.5. Analysis  
Analysis was carried out with GROMACS tools [61] and python scripts using the MDAnalysis 
package [70]. Prior to analysis all simulation systems were reoriented such that the membrane was 
aligned in the x-y plane. Electron density profiles were used to determine the depth of the peptide 
in the lipid bilayer. For this, the density of the lipid head groups, the lipid tails and the peptides 
across the lipid bilayer (i.e. along the z-axis) was calculated and plotted as a function of the 
distance from the bilayer centre. The density of the lipid head groups and lipid tails were averaged 
over the eight independent simulations while the density of the peptide was calculated for each 




To estimate the orientation of the peptide when bound to the membrane the angle between the 
peptide and the membrane surface was calculated. The orientation of the peptide was represented 
by a plane running through Cα of three residues on opposing sides of the peptide. The surface of 
the membrane was approximated by the x-y plane of the simulation system. For each independent 
simulation, the last 200 ns of the trajectory were used to calculate angles as a function of 
simulation time. From this data, ‘box-and-whiskers-plots’ were created in which the bottom, middle 
and top of the box represent the 25th, 50th and 75th percentile, respectively, and the whiskers 
represent the 10th and 90th percentile. 
 
To determine whether some residues interact more frequently with the lipid bilayer than others, a 
per-residue analysis of the minimum distance between the peptide and the lipid bilayer was carried 
out. The last 200 ns of each independent simulation were combined to form a single trajectory for 
the POPC simulations and another single trajectory for the POPC/POPS simulations. These 
trajectories were used to calculate a per-residue normalised frequency of finding a given residue 
within 0.35 nm of a lipid molecule. For example, a normalised frequency of 0.40 for a given residue 
means that this residue is within 0.35 nm of the lipid bilayer for 40% of the simulation time in the 
combined trajectory. The average and standard deviation of the normalised frequencies over all 
residues were calculated and used to identify residues that show a normalised frequency at least 
one standard deviation above or below the average.  
 
The total and hydrophobic solvent accessible surface area (SASA) of each peptide was calculated 
using a probe of 0.14 nm. For the hydrophobic SASA only Ala, Leu, Val, Ile, Pro, Phe, Met and Trp 
resides were used. As these peptides are charged species the dipole is not formally defined. The 
dipole can be calculated but it is dependent upon the origin of the coordinates i.e. for charged 
species the dipole is no longer invariant upon translations. However, to make a qualitative 
comparison between the different peptides we estimated the residual dipole that is invariant of 
rotation and position in the coordinate system as described by Buckingham [71]. In the tool used in 
this study (g_dipole found in the GRAOMCS package) this is achieved by subtracting the net 
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charge at the centre of mass of the molecule. The residual dipole moment of each peptide was 
estimated using the GROMACS tool g_dipoles, in which the net charge is subtracted at centre of 
mass of the molecule. 
 
3. Results  
 
The aim of this study was to compare the ability of pore blocking and gating modifier peptides to 
bind to phospholipid bilayers and determine whether membrane binding is a prerequisite for the 
activity of GMs. For this study we chose four peptides with pharmacological potential, including two 
PBs (ShK and KIIIA) and two GMs (Hd1a and ProTx-I) that differ in sequence, source, biophysical 
properties and molecular target (Fig. 1A).  
 
3.1. Phospholipid binding activity of pore blockers and gating modifiers followed by SPR 
SPR was used to compare the affinity of the four peptides for neutral (POPC) and negatively 
charged (POPC/POPS 4:1) membranes. Cell membranes in eukaryotic cells are in the fluid phase 
and have an asymmetric phospholipid composition; in particular, the outer leaflet is neutral and 
mainly composed of phospholipids containing phosphatidylcholine (PC) headgroups, whereas the 
inner leaflet contains ~20% of negatively-charged phosphatidylserine (PS)-phospholipids in 
addition to zwitterionic phospholipids (mainly with PC- or phosphatidylethanolamine (PE)-
headgroups). Thus, POPC bilayers, fluid at 25 ºC, were used here to mimic the neutral outer 
leaflet, whereas POPC/POPS bilayers mimic the negatively-charged inner leaflet. As mentioned 
above, some gating-modifier toxins have been proposed to only bind to anionic bilayers, which 
suggests that the VSD binding site for these toxins might be close to the cytoplasmic leaflet.  
 
Sensorgrams and dose-response curves revealed that both pore-blocking peptides, ShK and KIIIA, 
have low affinity for POPC and POPC/POPS bilayers (Fig. 2), indicative of a weak ability to bind 
and/or insert into lipid membranes. Comparison of the sensorgrams obtained with the two gating 
modifier peptides revealed that ProTx-I binds strongly to both neutral and anionic lipid membranes, 
whereas Hd1a binds only weakly to POPC and POPC/POPS bilayers (Fig. 2A). ProTx-I had higher 
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affinity, for anionic membranes (Fig. 2B), possibly due to increased electrostatic attractions 
between the positively-charged peptide and negatively-charged bilayer. Although all four peptides 
included in this study have a net positive charge (Fig. 1A), ProTx-1 has the smallest net charge 
(+2) and yet is the only peptide that binds significantly to anionic membranes. Interestingly, ProTx-I 
is the most hydrophobic peptide, as assessed by RP-HPLC retention time (Fig. 1A).  
 
3.2. Insertion of toxins into phospholipid bilayers followed by fluorescence spectroscopy 
Insertion of peptides into lipid membranes can induce changes in the membrane dipolar potential, 
which can be monitored by a shift in the fluorescence excitation spectrum of the dye di-8-ANEPPS 
[50]. Hence, to examine whether any of the venom peptides insert into the membrane, 
fluorescence excitation spectra of POPC/POPS (4:1) vesicles labelled with di-8-ANEPPS were 
recorded in the absence and presence of 20 µM of each peptide (Fig. 3A). Even at concentrations 
much higher than required to inhibit channel activity, ShK, KIIA and Hd1a did not induce changes 
in the fluorescence excitation spectrum of di-8-ANEPPS, as expected based on their inability to 
bind to POPC/POPS (4:1) membranes measured by SPR. Interestingly, ProTx-I also did not 
change the fluorescence excitation properties of di-8-ANEPPS; this result suggests that ProTx-I 
does not insert deeply in the membrane, and instead might be adsorbed at the membrane 
interface. 
 
The fluorescence emission of Trp is sensitive to polar/apolar environment [50]; thus, to gain further 
information on the depth that the Trp residues penetrate into the membrane when ProTx-I is bound 
to lipid bilayers we followed the Trp fluorescence in the absence and presence of lipid vesicles. 
The fluorescence emission spectrum of ProTx-I (Fig. 3B) did not change upon titration with 
POPC/POPS (4:1) LUVs suggesting that the Trp residues do not insert deeply into the membrane 
[50]. 
 
Acrylamide is an aqueous soluble fluorescence quencher unable to insert into lipid membranes 
and thus it selectively quenches Trp residues exposed to an aqueous environment. Identical 
ProTx-I fluorescence emission quenching efficiency by acrylamide in the absence and presence of 
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POPC/POPS (4:1) vesicles (Fig. 3C) also support the hypothesis that Trp residues within ProTx-I 
do not insert deeply into the lipid bilayer. 
 
3.3. Simulations of ProTx-I in the presence of POPC   
We used MD simulations to model the interaction of ProTx-I with POPC bilayers in order to gain 
information about the depth and orientation of ProTx-I in the membrane, and to identify regions of 
the peptide that mediate its interaction with lipids. Eight independent 300-ns simulations of ProTx-I 
in the presence of POPC bilayers were performed. In all simulations, the peptide freely diffuses in 
the aqueous phase for ~50 ns before binding to the membrane. ProTx-I is stabilised by three 
disulfide bonds arranged in an inhibitory cystine knot (ICK) motif, which provides the peptide with 
high structural stability [72]. To check that the peptide is as rigid in the presence of a lipid bilayer 
as it is in solution we compared the structure of the peptide in the two environments. The heavy-
atom Root-Mean Square Deviation (RMSD) as a function of time from the simulation of the peptide 
in water was compared to the RMSD from the simulations of the peptide in the presence of POPC. 
In water the peptide shows an average RMSD of 0.09 ± 0.04 nm (average ± 1 standard deviation) 
and in the presence of POPC the average RMSD is 0.09 ± 0.02 nm. This indicates that the binding 
of the peptide to the lipid bilayer does not induce any changes in the overall fold of the peptide.  
 
The depths to which the peptide penetrated the membrane were estimated by calculating density 
profiles of the lipid head groups, lipid carbon tails and peptide along the normal of the membrane 
(Fig. 4A). The data suggest that ProTx-I spends the majority of the time at the water-lipid interface, 
partially buried in the lipid head group region and partially exposed to the aqueous environment 
(Fig. 4C and 4D). Occasionally, part of the peptide inserts into the hydrophobic core of the bilayer. 
This position of the peptide is consistent with the observation from the fluorescence experiments.  
 
The orientation of the peptide when bound to the membrane was estimated by calculating the 
angle between the peptide and the surface of the lipid bilayer from the eight independent 
simulations (Fig. 4B), after the peptide was equilibrated for 100 ns in each simulation system. An 
orientation angle >45º is indicative of the peptide lying relatively flat on the membrane surface 
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(Fig. 4C) whereas an orientation angle <45° indicates a more upright position (Fig. 4D). Box plots 
indicate that the peptide did not adopt a preferred orientation over the timescale of the simulations. 
However, in most orientations adopted by the peptide the hydrophobic residues Trp5, Leu6, Gly7, 
Trp27 and Trp30, which are clustered on one face of the peptide (white in Fig. 4C and 4D), mostly 
pointed towards the lipid headgroups, whereas the polar residues (shown in green) were more 
likely to be water exposed. These hydrophobic residues form part of the hydrophobic face of 
ProTx-I (residues Trp5, Leu6, Gly7, Gly8, Gly26, Trp27, Val 29, Trp30 and Phe34; see Fig. 1B). 
When bound to the membrane the number of POPC molecules within 0.5 nm of the peptide 
fluctuates between 3 and 20. Averaged over the 8*300 ns of simulations there are 6–8 lipid 
molecules close to the peptide and further analysis of the lipid residency around the peptide 
showed that the peptide forms stable interactions with a number of selected lipid molecules rather 
than short-lived interactions with alternating lipids. This suggests that once the peptide is bound it 
is ‘dragged’ along the membrane surface by the diffusing lipids. 
 
To quantitatively assess whether some residues are more likely to interact with the lipid bilayer, we 
calculated the normalised frequency of finding a residue within 0.35 nm of a lipid molecule (Fig. 
5A). This analysis revealed that residues Glu1, Cys2, Tyr4, Trp5, Leu6, Cys16, Lys17 and Tpr30 
are more likely to be close to the lipid bilayer (marked with asterisks in Fig. 5A). Notably, Trp5, 
Leu6 and Trp30 account for 77% of the solvent accessible surface area of the hydrophobic face of 
the peptide. Residues Leu19, Val20, Cys21, Ser22, Arg23, Cys28 and Thr33 are, on average, less 
likely to interact with the lipid bilayer. These residues are located on the more polar face of the 
peptide situated opposite the hydrophobic surface (see Fig. 1B). Collectively, the simulation results 
suggest that ProTx-I is localised at the water-lipid interface of the POPC membrane with the 
majority of the hydrophobic face buried in the lipid headgroups, whereas the polar face of the 
molecule is exposed to the aqueous environment.  
 
3.3. Simulations of ProTx-I in the presence of POPC/POPS (4:1) 
The SPR data showed that ProTx-I exhibits a stronger affinity for, and a slower dissociation rate 
from, membranes that contain anionic phospholipids. To investigate the effect of anionic lipids on 
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the lipid-ProTx-I interaction, we carried out MD simulations of ProTx-I in the presence of a 
POPC/POPS (4:1) lipid bilayer. As with the simulations in the presence of POPC, the peptide 
remained as rigid upon binding to the POPC-POPS bilayer as in solution. The average RMSD of 
the peptide in the presence of POPC-POPS bilayer is 0.09 ± 0.03 nm (average ± 1 standard 
deviation) while in water it is 0.09 ± 0.04 nm. In all eight simulations, the peptide bound to the lipid 
bilayer within the first 10 ns, significantly faster than in simulations with pure POPC. The 
membrane depth, relative orientation and interaction surface of the peptide were calculated as 
described for the simulations with pure POPC. The density profiles extracted from the 
POPC/POPS simulations (Fig. 6A) show that the depth of the peptide is not affected by the 
presence of the negatively charged lipids. Comparison of the range of angles adopted by the 
peptides across the eight independent simulations in the presence of zwitterionic (Fig. 4B) and 
charged lipids (Fig. 6B) showed that the peptide samples a similar range of relative orientations in 
the two lipid environments. However, the variation within a given simulation is reduced in the 
presence of anionic lipids suggesting that peptide binds tighter to the surface. Indeed, analysis of 
the time-dependent orientation of the peptide showed that in the presence of charged lipids the 
peptides remains longer in a given orientation. Per-residue analysis of the lipid interactions (Fig. 
6C) showed that residues Glu1, Cys2, Tyr4, Lys17, His18 and Trp30 are more likely to be close to 
the membrane while residues Cys9, Cys21, Ser22, Arg23, Cys28 and Val29 are less likely to be in 
contact with the lipids. It is interesting to note that even in the presence of anionic POPS, the 
positively charged residues Arg23 and Arg24 show little interaction with the membrane surface. 
The arginine residues are located on the more polar face of the peptide, suggesting that while the 
presence of anionic lipids enhances the rate of association of the toxin with the membrane, burial 
of hydrophobic residues is the main driving force that determines the relative orientation of ProTx-I 
on the membrane. This is consistent with the fact that there was no increase in the number of 
POPS molecules around the peptide. That is, the ratio of POPC and POPS lipids within 0.5 nm of 
the peptide is, on average, the same as in the bulk of the lipid. Comparison of the normalised lipid-
residency frequencies for ProTx-I in the presence of POPC only (Fig. 5A) and POPC/POPS (Fig. 
6C) shows that Lys17, His18 and Trp30 interact more frequently with membranes containing 
anionic lipids. Overall there is a large overlap between ProTx-I residues that form the interaction 
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surface with POPC and POPC/POPS. Residues Glu1, Cys2, Tyr4, Trp5, Lys17 and Trp30 
frequently interact with both POPC and POPC/POPS membranes (Fig. 5A and 6C) and likely form 
the dominant lipid interaction surface of ProTx-I (Fig. 5D). Collectively, the data suggest that in 
presence of POPC or POPC/POPS the peptide sits at the water-lipid interface with its hydrophobic 
face buried in the bilayer and the more polar face exposed to solvent. The overall relative 
orientation of the peptide is very similar but the presence of anionic lipids appears to have a slight 
anchoring effect. The faster partitioning and ‘anchoring’ effect in the presence of anionic lipids is 
consistent with the increased binding affinity and slower off-rates observed in the SPR 
experiments. 
 
4. Discussion  
 
Disulfide-rich peptides isolated from animal venoms typically have well-defined three-dimensional 
structures and remarkable stability [6-9]. Many of these peptides inhibit human VGICs with 
exquisite selectivity and high potency [11, 12, 15, 19]. Consequently, many venom peptides have 
been investigated as potential insecticides or therapeutics and as pharmacological tools to study 
the (patho)physiology of VGICs [11-14, 16-18, 73] . Venom peptides can act as PBs, inhibiting the 
flow of ions through VGICs by blocking the extracellular face of the channel pore, or they can act 
as GMs by stabilising particular states in the gating cycle via interactions with the membrane-
embedded VSDs. It has been proposed that GMs act via a ‘membrane-access’ mechanism in 
which lipid binding is a prerequisite for interaction with their cognate VSDs [27]. However, the 
generality of this mechanism has been questioned [31, 33, 34]. Here we examined the potential of 
two PBs, KIIIA and ShK, and two GMs, Hd1a and ProTx-I, to bind to neutral and anionic 
phospholipid membranes. SPR analysis indicated that neither Hd1a nor either of the two PBs 
interacted with neutral or anionic lipid bilayers. Only ProTx-I interacted significantly with model 
membranes. Hd1a potently inhibits the human NaV1.7 channel (IC50 ~ 110 nM) via interaction with 
the domain II VSD [19]. This is in agreement with previous studies which reported that other GMs 
including anthopleurin B (ApB) and Leiurus toxin V (LqqV) [31], huwentoxin-IV [32] and HpTx2 [34] 
showed only weak or no binding to phospholipid membranes. The combined data provide further 
Authors	  manuscript	  
19/34	  
evidence that membrane partitioning is not an intrinsic property of all GMs and that the 
‘membrane-access’ mechanism cannot be generalised.  
 
The availability of data on the lipid-binding activity of a number of venom peptides allows a 
comparison of their structural and chemical properties to help elucidate why only selected GMs 
bind to membranes. It has been suggested that the membrane partitioning of certain GMs is a 
consequence of their amphipathic surface profile in which one face of the peptide contains a 
cluster of hydrophobic residues surrounded by polar, mainly basic, residues [26, 28-31, 35, 37]. 
Fig. 7 compares the surface composition of two PBs and six gating modifier peptides while Table 1 
lists the overall charge, the total and hydrophobic solvent accessible surface areas and the 
residual dipole moments of the six gating modifier peptides and the two pore blocking peptides 
investigated in this study. 
 
The GMs Hd1a and huwentoxin-IV [32] do not bind to phospholipid membranes whereas the four 
GMs VsTx1 [26, 27], SGTx1 [28, 29], hanatoxin [30] and ProTx-I show membrane partitioning. 
Despite the distinctly different membrane-binding properties of these GMs, they are all amphipathic 
with a hydrophobic cluster and surface-exposed anionic and cationic residues. Furthermore, the 
peptides have similar overall charge and their hydrophobic solvent accessible surface area (SASA) 
as a percentage of total SASA are very similar. While Hd1a and huwentoxin-IV have a higher 
residual dipole moment than the GMs that do not bind to membranes, a comparison of a much 
larger set of peptides is needed to determine whether the residual dipole moment can be used to 
reliably predict the phospholipid binding activity of a peptide. Taken together, these results suggest 
that the ability of gating modifier peptides to bind membranes cannot be predicted based solely on 
the presence of a hydrophobic cluster and the amphipathic nature of the peptide, the overall 
charge of the peptide or its residual dipole moment. 
 
Although the presence of a hydrophobic and polar face might in itself not be sufficient to predict 
that a given peptide will bind weakly or strongly to lipid membranes, there is evidence that, for 
those GMs that do partition into membranes, their amphipathic nature determines their position 
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on/in the membrane. Our fluorescence measurements suggest that ProTx-I binds at the water-lipid 
interface and MD simulations suggest that the peptide has its hydrophobic face buried in the lipid 
headgroups with its polar face exposed to the solvent. This is consistent with a number of previous 
studies that investigated membrane partitioning of the GMs VsTx1, SGTx1 and hanatoxin using a 
range of experimental techniques and/or MD simulations [26, 28, 30, 35, 37]. In the case of ProTx-
I, residues Glu1, Cys2, Tyr4, Trp5, Lys17 and Trp30 appear to form the dominant lipid interaction 
surface of ProTx-I in the presence of both neutral and anionic phospholipid membranes. These 
residues form a distinctly different surface than the pharmacophore that mediates the interaction of 
ProTx-I with Nav1.2 and the transient receptor potential ankyrin 1 (TRPA1) channel [56].  
 
5. Conclusions  
 
In this study, we compared the lipid-binding propensity of venom-derived PBs and GMs. None of 
the PBs interacted significantly with lipid membranes, consistent with their solvent-exposed 
extracellular binding site. Although some GMs are able to bind and insert into membranes, we 
provide evidence that this is not a prerequisite for gating modification via interaction with voltage 
sensor domains. We have shown that the gating-modifier ProTx-I binds to both neutral and anionic 
phospholipids. The peptide does not insert deeply into the lipid bilayer but binds to the water-lipid 
interface, with its hydrophobic face buried in the lipid headgroups and its polar face exposed to the 
solvent.  
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Table 1. Charge, solvent accessible surface area (SASA) and residual dipole moments of 
the pore blockers (PB) and of six gating modifiers (GM) with and without phospholipid 
binding activity. MOA = Mechanism of action. 
 










ShK PB No +7 1510 23% 98 
KIIIA PB No +2 2777 61 % 37 
Hd1a GM No +3 2931 61 % 295 
HuwentoxinIV GM No +4 3148 55 % 206 
SGTx1 GM Yes +2 2842 47 % 181 
Hanatoxin GM Yes +2 3330 50 % 117 
VsTx1 GM Yes +3 2994 57 % 109 








Fig. 1. Sequence and structure of peptides used in this study. (A) Sequence, source, ion 
channel target, overall charge, RP-HPLC retention time, and type of channel inhibition. Disulfide-
bonds are indicated by horizontal lines below the sequences. (B) Three-dimensional structure of 
the peptides. The ribbon representations on the left are coloured according to secondary structure 
(α-helices in purple and β-strands in blue), while the surface representations on the right are 
coloured according to residue type (hydrophobic residues in white, polar (uncharged) residues in 






Fig. 2. SPR analysis of lipid binding by pore-blocking and gating-modifier toxins. (A) 
Sensorgrams obtained upon injection of 64 µM peptide (ShK, KIIIA, ProTx-I or Hd1a) over 
deposited POPC or POPC/POPS (4:1) bilayers during association (180 s) and dissociation (600 s). 
Response units (RU) were converted into mass (1 RU ~1 pg/mm2 of peptide or lipid) and 
normalised to peptide-to-lipid ratio (mol/mol) in order to allow comparison of the different peptides. 
This was necessary as the peptides have different molecular weights, and different lipid systems 
require different amounts of lipid to cover the chip surface. ShK, KIIIA, or Hd1a all display 
sensorgrams typical of low peptide-lipid binding. ProTx-I shows a high P/L (mol/mol) signal at the 
end of association and a slow off rate, characteristic of a peptide with affinity for lipid bilayers. (B) 
Peptide-to-lipid ratio obtained after injection of peptide for 170 s over POPC or POPC/POPS 





Fig. 3. Examination of peptide insertion into lipid membrane using fluorescence 
spectroscopy. (A) Di-8-ANEPPS differential excitation spectra obtained with 200 µM of 
POPC/POPS (4:1) LUVs labelled with 4 µM Di-8-ANEPPS in the presence of 20 µM of ShK, KIIA, 
H1d1a or ProTx-I. The absence of a shift in the differential spectra suggests no change in the 
membrane dipolar potential. (B) Fluorescence emission spectra of 25 µM ProTx-I in the absence 
(blue) and presence of various concentrations of POPC/POPS (4:1) LUVs (0.05, 0.1, 0.2, 0.5, 1, 
1.5 and 2 mM are shown in black and 4 mM Lipid is shown in red). No significant blue shift or 
increase in the quantum yield was found. (C) Acrylamide quenching of fluorescence emission 
intensity (ex = 290 nm, em =348 nm) of 25 µM ProTx-I in buffer (10 mM HEPES, 150 mM NaCl 
pH 7.4) or in the presence of 1 mM POPC/POPS (4:1) vesicles. Data are represented as Stern 
Volmer plots. Calculated KSV is 30.1 ± 0.3 M-1 in buffer and 31.7 ± 0.8 M-1 in the presence of 





Fig. 4. Position and orientation of ProTx-I in POPC bilayers calculated from MD simulations. 
(A) Density profile of the POPC lipid bilayer and ProTx-I along the normal of the membrane. 
Density of lipid head groups (dashed line) and lipid tails (dotted line) were averaged over the eight 
independent simulations. The density profiles of the peptide were calculated separately for each 
simulation and are shown in colour. (B) Boxplot showing the angle between the peptide and lipid 
bilayer surface from eight simulations. Bottom, middle and top of the box represent the 25th, 50th 
and 75th percentile while whiskers represent the 10th and 90th percentile. (C,D) Snapshots from 
simulations showing the orientation of the peptide relative to the membrane surface corresponding 
to angles of ~5° and ~50°. The peptide surface is coloured by residue type (hydrophobic, white; 






Fig. 5. POPC interaction surface of ProTx-I calculated from MD simulations. (A) Normalised 
frequency of finding a ProTx-I residue within 0.35 nm of a POPC bilayer calculated from eight 
independent MD simulations. The lipid-residency frequency averaged over all residues is shown by 
the solid horizontal line, while the dashed lines indicate ± one standard deviation from the average. 
Residues with a normalised frequency below or above one standard deviation from the average 
are marked with a cyan or orange asterisk, respectively. Glu1, Cys2, Tyr4, Trp5, Cys16, Lys17 and 
Trp30 are more likely to contact the lipid bilayer, while residues Leu19, Val20, Cys21, Ser22, 
Arg23, Cys28 and Thr33 are more likely to point away from the membrane. (B) Snapshots from 
MD simulations showing the orientation of ProTx-I relative to the membrane; residues that are 





Fig. 6. Position and orientation of ProTx-I in POPC/POPS bilayers calculated from MD 
simulations. (A) Density profile of the POPC/POPS lipid bilayer and ProTx-I along the normal of 
the membrane. Density of lipid head groups (dashed line) and lipid tails (dotted line) were 
averaged over the eight independent simulations. Density profiles of the peptide were calculated 
separately for each simulation and are shown in colour. (B) Boxplot showing the angle between the 
peptide and lipid bilayer surface from eight simulations. Bottom, middle and top of the box 
represent the 25th, 50th and 75th percentile, respectively. Whiskers represent the 10th and 90th 
percentile. (C) Normalised frequency of finding a residue within 0.35 nm of the lipid bilayer 
calculated from the combined MD simulations. The lipid-residency frequency averaged over all 
residues is shown by the solid horizontal line, while the dashed lines indicate ± one standard 
deviation from the average. Residues with a normalised frequency below or above one standard 
deviation from the average are marked with a cyan or orange asterisk, respectively. Glu1, Cys2, 
Tyr4, Lys17, His18 and Trp30 are more likely to contact the lipid bilayer, while residues Cys9, 
Cys21, Ser22, Arg23, Cys28 and Val29 are less likely to be close to the membrane. (D) Surface 
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representation of ProTx-I with residues more or less likely to contact the lipid bilayer shown in 
orange and cyan, respectively. Solid coloured residues are part of the interaction surface in 







Fig. 7. Comparison of pore blockers and gating modifiers with and without phospholipid 
binding activity. Peptides are shown in surface representation and coloured by residue type 
(hydrophobic, white; polar (uncharged), green; positively charged, blue; and negatively charged, 
red). The phospholipid binding activity of peptides marked with an asterisk are based on results 
from this study. The phospholipid binding activities of VsTx1 [27], SGTx1 [28, 29], hanatoxin [29, 
30] and huwentoxin IV [32] were reported in previous studies.  
	  
 
